You are here

Eli Lilly

Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi

Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi

Reuters

personalized medicine

Flag link:

Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt

Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt

Fierce Pharma

Flag link:

Most insurers don't cover Eli Lilly's half-priced insulin

Most insurers don't cover Eli Lilly's half-priced insulin

Beckers Hospital Review

Flag link:

Apple, Eli Lilly research whether devices can detect dementia signs

Apple, Eli Lilly research whether devices can detect dementia signs

Medtech Dive

Flag link:

Lilly shuffles executives overseeing oncology and M&A

Lilly shuffles executives overseeing oncology and M&A

Biopharma Dive

Flag link:

Eli Lilly confirms probe by New York’s Attorney General over insulin prices

Eli Lilly confirms probe by New York’s Attorney General over insulin prices

CNBC

Flag link:

Racing after the leaders, Eli Lilly's migraine drug clears another pivotal study

Racing after the leaders, Eli Lilly's migraine drug clears another pivotal study

Endpoints

clinical trials

chronic migraine

episodic migraine

Flag link:

3 Lung Cancer Stocks That Could Soar in September

3 Lung Cancer Stocks That Could Soar in September

Motley Fool

Flag link:

New York investigating 3 insulin makers' pricing strategies

New York investigating 3 insulin makers' pricing strategies

Beckers Hospital Review

Flag link:

Lilly's Emgality powers ahead with 'best-in-class' CGRP access

Lilly's Emgality powers ahead with 'best-in-class' CGRP access

Fierce Pharma

Teva Pharmaceutical

Flag link:

Lilly cancer push boosted by survival benefit to key drug

Lilly cancer push boosted by survival benefit to key drug

Biopharma Dive

metastatic breast cancer

clinical trials

Flag link:

Lilly drops PD-L1/TIM-3 bispecific from clinical pipeline

Lilly drops PD-L1/TIM-3 bispecific from clinical pipeline

Fierce Biotech

bispecific antibodies

Flag link:

After painting a poor safety profile, Pfizer and Eli Lilly are shooting for a new pain drug OK anyway

After painting a poor safety profile, Pfizer and Eli Lilly are shooting for a new pain drug OK anyway

Endpoints

Flag link:

The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Yahoo/Benzinga

Leap Therapeutics

Cidara Therapeutics

Spark Therapeutics

clinical trials

Flag link:

In a first, Lilly's ready-to-use rescue hypoglycemia powder wins US approval

In a first, Lilly's ready-to-use rescue hypoglycemia powder wins US approval

Endpoints

Flag link:

These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger

These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger

Investors Business Daily

Bristol-Myers Squibb

Gilead Sciences

Flag link:

Emgality-maker Lilly courts payers with new migraine ER data

Emgality-maker Lilly courts payers with new migraine ER data

Fierce Pharma

cluster headache

Teva Pharmaceutical

Flag link:

Amgen, Novartis BACE Inhibitor Joins List of Failed Alzheimer’s Drugs

Amgen, Novartis BACE Inhibitor Joins List of Failed Alzheimer’s Drugs

Xconomy

Alzheimer's disease

BACE inhibitors

Flag link:

Bayer floats animal health merger with Lilly spinoff Elanco: report

Bayer floats animal health merger with Lilly spinoff Elanco: report

Fierce Pharma

Flag link:

Array, Pierre Fabre bowel cancer therapy ‘could replace chemo’

Array, Pierre Fabre bowel cancer therapy ‘could replace chemo’

Pharmaforum

Array Biopharma

colorectal cancer

clinical trials

Flag link:

Pages